Deal

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires WIL Research

April 2016 full acquisition ready

Snapshot

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired WIL Research for approximately $585 million in cash (purchase price $604.8 million including assumed liabilities) in April 2016. The transaction was structured as all cash. WIL Research is a United States (global operations)-based Discovery and Safety Assessment (DSA) business.

Acquirer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Target
WIL Research
Value
approximately $585 million in cash (purchase price $604.8 million including assumed liabilities)
Date
April 2016
Type
full acquisition
Status
ready
01 Scorecard

The deal at a glance

Private-market deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires WIL Research
Deal value
approximately $585 million in cash (purchase price $604.8 million including assumed liabilities)
Sector
Discovery and Safety Assessment (DSA)
Date
April 2016
VectorShift
Made on VectorShift

About this deal

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired WIL Research for approximately $585 million in cash (purchase price $604.8 million including assumed liabilities), a transaction completed in April 2016, structured as all cash.

WIL Research operates in Discovery and Safety Assessment (DSA), is based in United States (global operations). WIL Research was a premier provider of safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical and agricultural and industrial chemical companies worldwide.

The acquisition enhanced our position as a leading global early-stage CRO by strengthening our ability to partner with clients across the drug discovery and development continuum.

Expected non-GAAP EPS accretion of at least $0.20 in 2016 and $0.45-$0.50 in 2017 Discovery and Safety Assessment (DSA) segment

In addition to enhancing our value proposition for clients, we believe that the acquisition of WIL Research will generate value for shareholders, driving profitable revenue growth and non-GAAP earnings per share accretion of at least $0.20 in 2016 and $0.45 to $0.50 in 2017.
James C. Foster, Chairman, President and Chief Executive Officer, Charles River Laboratories
Advisors not disclosed

No advisory firms have been disclosed for this transaction.

Sources Press releaseSEC filing Last updated

See how VectorShift works for your firm

Request Demo